Health Condition 1: H408- Other glaucoma
Conditions
Interventions
Intervention1: DORZOLAMIDE: EYEDROP DORZOLAMIDE 2% TDS (THRICE A DAY) FOR 1 MONTH
Intervention2: NETARSUDIL: EYEDROP NETARSUDIL 0.02% HS (ONCE A DAY AT NIGHT) FOR 1 YEAR
Sponsors
Dr Rajendra Prasad Centre for Ophthalmic Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Preperimetric Glaucoma- Age over 40 years Open angle in gonioscopy Baseline IOP = 25mmHg Best-corrected visual acuity 20/40 or better (refractive error ± 5.0D spherical; ± 3.0D cylinder) Abnormal circumpapillary RNFL thickness (cpRNFLT) in at least one quadrant on OCT scan A visual field within the normal limits of a glaucoma hemifield test, with pattern standard deviation (PSD) greater than 5%, confirmed in at least two examinations Early Glaucoma- BCVA 20/40 or more (refractive error ± 5.0D spherical; ± 3.0D cylinder) Open angles on gonioscopy Baseline IOP = 25mmHg Features suggestive of glaucomatous optic neuropathy such as cup-disc ratio >0.6 and any diffuse or focal neuroretinal rim thinning 2 consecutive abnormal visual field tests defined as PSD outside 95% normal confidence limits and a GHT classified as ‘‘outside normal limits’’ as defined by the Hodapp-Parrish-Anderson (HPA) criteria for early glaucoma
Exclusion criteria
Exclusion criteria: Patients with moderate or advanced glaucoma (MD worse than -6 dB) Patients with media opacity precluding good-quality OCT scans such as corneal opacity, cataracts, etc. History of intraocular diseases, complicated intraocular surgery, secondary glaucoma Age Coexisting retinal disease (for example, diabetic retinopathy) Other diseases affecting visual field Patients on vasodilatory drugs such as Nitroglycerin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vessel Density(ONH AND MACULAR) USING OCTATimepoint: Day 1, 4 months, 8 months, 12 months(if possible) | — |
Secondary
| Measure | Time frame |
|---|---|
| Flux indexTimepoint: Day 1, 4 months, 8 months, 12 months(if possible);Macular Flow IndexTimepoint: Day 1, 4 months, 8 months, 12 months(if possible);pRNFL ThicknessTimepoint: Day 1, 4 months, 8 months, 12 months(if possible);Visual Field ChangesTimepoint: Day 1, 4 months, 8 months, 12 months(if possible) | — |
Countries
India
Contacts
Public ContactDr Vanaja Jain
All India Institute of Medical Sciences
Outcome results
None listed